Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: Neuropharmacology. 2007 Jun 28;53(3):447–454. doi: 10.1016/j.neuropharm.2007.06.009

Figure 2.

Figure 2

Neuropeptide levels in the substantia innominata, medial pulvinar thalamus and lateral thalamus in control (no drug history) or METH abusers. Data (n = 15–17 per group) are expressed as percentage of baseline ± S.E.M. *p < 0.05 versus control. Abbreviations are the same as Figure 1.